



## Pharmacometabolomics

Guest Editor:

### Dr. Richard Beger

Division of Systems Biology,  
National Center for Toxicological  
Research, US Food and Drug  
Administration, Jefferson, AR  
72079, USA

Deadline for manuscript  
submissions:

**closed (15 December 2019)**

### Message from the Guest Editor

Dear Colleagues,

Pharmacometabolomics or pharmacometabonomics, subsets of the greater metabolomics field, is the study of how differences in metabolites in an individual or subset of the population can be used to predict their varied responses to a drug or medical intervention. Metabolomics profiles obtained prior, during or after a drug or medical intervention can provide predictive, prognostic, and pharmacodynamic response biomarkers to a drug or medical intervention. This Special Issue is devoted to the applications of pharmacometabolomics. Topics covered by this Special Issue will include (not exclusively): metabolomics from nonclinical or clinical drug studies, pharmacometabolomics studies that can differentiate gender or racial differences in a drug response, precision medicine studies that combine pharmacometabolomics with pharmacogenomics data, and pharmacometabolomics studies that include pharmacokinetics and pharmacodynamics information.

Dr. Richard Beger  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy  
2. Formerly Professor of Internal Medicine, School of Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

## Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Biochemistry & Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

## Contact Us

*Metabolites* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/metabolites](http://mdpi.com/journal/metabolites)  
[metabolites@mdpi.com](mailto:metabolites@mdpi.com)  
X@MetabolitesMDPI